CRBN and plasma cell myeloma: In the context of multiple myeloma, thalidomide and its derivate pomalidomide could promote the degradation of Ikaros by altering the substrate specificity of cereblon (CRBN), the target of the CUL4-RBX1-DDB1-CRBN (also known as CRL4CRBN E3 ubiquitin ligase.